Alleviating hypoxia to improve cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Vascular Biology

Background:

• Tumor hypoxia, caused by abnormal tumor vasculature, creates an immunosuppressive tumor microenvironment (TME).
• Hypoxia promotes angiogenesis, metabolic reprogramming, extracellular matrix remodeling, epithelial-mesenchymal transition (EMT), p53 inactivation, and immune evasion, hindering immunotherapy.
• Dysfunctional tumor blood vessels are a major barrier to effective cancer immunotherapy.

Purpose of the Study:

• To review the mechanisms of tumor hypoxia and its impact on cancer immunotherapy.
• To discuss strategies for inducing tumor vascular normalization.
• To summarize evidence supporting vascular normalization in combination with cancer immunotherapy.

Main Methods:

• Literature review of tumor hypoxia mechanisms.
• Analysis of vascular normalization strategies.
• Synthesis of data on combined vascular normalization and immunotherapy.

Main Results:

• Vascular normalization improves oxygen delivery and reverses hypoxia-induced immunosuppression.
• Restored vascular function potentiates anti-tumor immune responses.
• Evidence supports combining vascular normalization with immunotherapy to overcome hypoxia-induced resistance.

Conclusions:

• Targeting tumor hypoxia via vascular normalization is a promising strategy to enhance cancer immunotherapy efficacy.
• Vascular normalization can improve clinical outcomes for cancer patients undergoing immunotherapy.
• Further research and clinical application of vascular normalization in combination with immunotherapy are warranted.